Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, $132 per Share, Adding Caplyta to Neuroscience Portfolio

Jan 13, 2025, 10:44 AM

Johnson & Johnson has confirmed its acquisition of Intra-Cellular Therapies Inc. for $14.6 billion, paying $132 per share in cash. This deal marks a significant move by Johnson & Johnson to bolster its neuroscience portfolio, adding Intra-Cellular's drug Caplyta, which is approved for treating schizophrenia and bipolar depression. The acquisition comes ahead of the JPM Healthcare conference and follows a patent settlement that cleared the way for the deal. Intra-Cellular, co-founded by Sharon Mates and based on research by Nobel laureate Paul Greengard, had a market cap of about $10 billion before the announcement. The deal is seen as part of a broader trend of large drugmakers reentering the neuroscience field, with Intra-Cellular's Caplyta potentially expanding into treatment for major depressive disorder.